These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20072731)

  • 1. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?
    López-Longo FJ; Sánchez-Ramón S; Carreño L
    Drug News Perspect; 2009 Nov; 22(9):543-8. PubMed ID: 20072731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
    López-Longo FJ; Oliver-Miñarro D; de la Torre I; González-Díaz de Rábago E; Sánchez-Ramón S; Rodríguez-Mahou M; Paravisini A; Monteagudo I; González CM; García-Castro M; Casas MD; Carreño L
    Arthritis Rheum; 2009 Apr; 61(4):419-24. PubMed ID: 19333979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations.
    Korkmaz C; Us T; Kaşifoğlu T; Akgün Y
    Clin Biochem; 2006 Oct; 39(10):961-5. PubMed ID: 16979149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
    Sihvonen S; Korpela M; Mustila A; Mustonen J
    J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis.
    Korendowych E; Owen P; Ravindran J; Carmichael C; McHugh N
    Rheumatology (Oxford); 2005 Aug; 44(8):1056-60. PubMed ID: 15901902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
    van der Helm-van Mil AH; Verpoort KN; le Cessie S; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2007 Feb; 56(2):425-32. PubMed ID: 17265477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
    Bang SY; Lee KH; Cho SK; Lee HS; Lee KW; Bae SC
    Arthritis Rheum; 2010 Feb; 62(2):369-77. PubMed ID: 20112396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
    Panchagnula R; Rajiv SR; Prakash J; Chandrashekara S; Suresh KP
    J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of anti-cyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis].
    Araki C; Hayashi N; Moriyama M; Morinobu S; Mukai M; Koshiba M; Kawano S; Kumagai S
    Rinsho Byori; 2004 Dec; 52(12):966-72. PubMed ID: 15675342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.